# A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]

> **NCT05179603** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 14 (actual)

## Conditions studied

- Classic Hodgkin Lymphoma
- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** THOR-707
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05179603
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-07
- **Primary completion:** 2023-09-14
- **Final completion:** 2024-09-06
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Early discontinuation based on strategic sponsor decision not driven by any safety concerns
- **Last updated:** 2025-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05179603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05179603, "A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05179603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*